drugset / Trial / NCT05149391
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Phase 1
Completed
3 enrolled
Peking University
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.
Timeline
- Start
- 2021-07-20
- Primary completion
- 2024-01-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR039 | Cell therapy | — | Intravenous |